Skip to main content
PLOS Biology logoLink to PLOS Biology
. 2023 Oct 17;21(10):e3002329. doi: 10.1371/journal.pbio.3002329

Multidrug-resistant E. coli encoding high genetic diversity in carbohydrate metabolism genes displace commensal E. coli from the intestinal tract

Christopher H Connor 1,2, Amanda Z Zucoloto 2,3,4, John T Munnoch 5, Ian-Ling Yu 3, Jukka Corander 6,7,8, Paul A Hoskisson 5, Braedon McDonald 2,3,4,*, Alan McNally 1,*
Editor: Sebastian E Winter9
PMCID: PMC10581457  PMID: 37847672

Abstract

Extra-intestinal pathogenic Escherichia coli (ExPEC) can cause a variety of infections outside of the intestine and are a major causative agent of urinary tract infections. Treatment of these infections is increasingly frustrated by antimicrobial resistance (AMR) diminishing the number of effective therapies available to clinicians. Incidence of multidrug resistance (MDR) is not uniform across the phylogenetic spectrum of E. coli. Instead, AMR is concentrated in select lineages, such as ST131, which are MDR pandemic clones that have spread AMR globally. Using a gnotobiotic mouse model, we demonstrate that an MDR E. coli ST131 is capable of out-competing and displacing non-MDR E. coli from the gut in vivo. This is achieved in the absence of antibiotic treatment mediating a selective advantage. In mice colonised with non-MDR E. coli strains, challenge with MDR E. coli either by oral gavage or co-housing with MDR E. coli colonised mice results in displacement and dominant intestinal colonisation by MDR E. coli ST131. To investigate the genetic basis of this superior gut colonisation ability by MDR E. coli, we assayed the metabolic capabilities of our strains using a Biolog phenotypic microarray revealing altered carbon metabolism. Functional pangenomic analysis of 19,571 E. coli genomes revealed that carriage of AMR genes is associated with increased diversity in carbohydrate metabolism genes. The data presented here demonstrate that independent of antibiotic selective pressures, MDR E. coli display a competitive advantage to colonise the mammalian gut and points to a vital role of metabolism in the evolution and success of MDR lineages of E. coli via carriage and spread.


A mouse colonisation model reveals that a multidrug-resistant (MDR) strain of E. coli can displace commensal strains from the gut, and that unique selection pressures occurring in the MDR strain result in streamlining of their metabolism. Analysis of a curated set of 20,000 E. coli genomes shows that MDR lineages are associated with increased nucleotide sequence diversity in metabolism genes.

Introduction

Infections by multidrug resistant (MDR) gram-negative pathogens now represent one of the greatest global public health challenges of our generation, with the World Health Organisation declaring them of utmost international importance. Chief among these pathogens is MDR Escherichia coli, which are responsible for an alarming rise in the incidence of antimicrobial resistant (AMR) blood stream and urinary tract infections [1]. MDR in E. coli is heavily associated with the carriage of large MDR plasmids encoding extended spectrum beta-lactamases (ESBLs) and carbapenemases such as NDM, KPC, and Oxa-48 that confer resistance to third-generation cephalosporins and carbapenem classes of antibiotics, respectively [1]. Intriguingly, such plasmids are very rarely found in intestinal pathogenic E. coli such as E. coli O157 or common enteropathogenic and enterotoxigenic E. coli strains. Rather MDR plasmid carriage is concentrated in a number of lineages responsible for extra-intestinal pathogenesis such as blood stream and urinary tract infections [2].

Extra-intestinal pathogenic E. coli (ExPEC) is the name given to E. coli strains capable of causing extra-intestinal infections, but do not represent a phylogenetically distinct group of organisms. Rather ExPEC are found across the species phylogeny mainly in phylogroups B2, D, and F [3]. Recent longitudinal surveys of national blood stream infection isolates have shown the most common ExPEC lineages to be ST131, ST73, ST69, ST95, ST410, and members of the ST10 complex including ST167 [4,5]. Equally as intriguingly, MDR plasmids are not evenly distributed among these ExPEC lineages but rather their carriage is concentrated in a small number of highly successful, globally disseminated clones [2]. The most successful of these clones is clade C of ST131, the most common cause of MDR blood stream and urinary tract infections worldwide [6]. Other common MDR E. coli lineages include ST69, ST410, ST167, and ST648 [2].

What makes certain clones or lineages of E. coli successful MDR pathogens is an ongoing question. Recent analysis of longitudinal blood stream infection isolates from Norway shows that ST131 strains successfully emerged to be dominant in the absence of MDR plasmid carriage indicating MDR alone is not the driver of their success [5]. Analysis of longitudinal UK isolates shows that MDR alone is not sufficient to drive strains to complete dominance of the epidemiological landscape [4]. Recent evidence suggests an important phenotype that differentiates MDR E. coli from other lineages is their ability to rapidly and asymptomatically colonise the intestinal tract of humans. The COMBAT study of 1,847 people travelling from the Netherlands to Asia, Africa, and South America found that 34% of those travelling acquired an ESBL E. coli in their intestinal tract during their journey, with that number increasing to 75% of those travelling to Asia [7]. Of those colonised in the study, 11% were colonised for up to 12 months. A small scale study of University of Birmingham students found that all participants travelling to Asia became colonised by an ESBL E. coli, with genomic analysis confirming that this was due to acquisition of a new MDR strain and not the resident commensal E. coli becoming MDR [8]. A recent study of medical personnel travelling to Laos sampled travellers in real time to show that every single person was colonised by an MDR E. coli during travel, with colonisation occurring within days after arrival [9]. A very recent study by our group deploying metagenomic sequencing on the COMBAT study samples showed that when people were colonised by an MDR E. coli, there was no detectable impact on diversity or composition of the wider gut microbiome as a result of MDR colonisation [10]. While observational studies have yielded hypothesis-generating data suggesting stain-to-strain competition, this has never been directly tested in vivo.

Studies investigating genetic determinants differentiating MDR E. coli lineages from the rest of the population have also uncovered a number of parallel observations. Studies comparing clade C ST131 to its ancestral population show a collection of adaptive nucleotide substitutions in chromosomal promoter regions associated with the specific plasmid carried by the strain [11], a pattern which has also been seen in ST167 [12]. A high-resolution study of ST131 using a pangenome approach to identify allelic variations in genes found a highly elevated number of nucleotide substitutions in genes involved in mammalian colonisation including anaerobic metabolism, iron acquisition, and adhesins. This pattern was not seen in successful non-MDR ExPEC lineages such as ST73 [13]. Such allelic diversity in anaerobic metabolism genes has also been seen in ST167 and ST648 [12,14], and it was also shown that recombination of new alleles of fhu iron acquisition genes was the key evolutionary event underpinning the emergence the carbapenem-resistant B4/H24RxC clone in the ST410 lineage [15]. We hypothesise that these genetic adaptations may contribute to more effective colonisation of the mammalian gut.

Here, we use a gnotobiotic mouse model of intestinal colonisation to directly test the hypothesis that MDR E. coli can outcompete commensal E. coli via inter-strain competition to establish dominant colonisation of the intestinal tract in vivo in the absence of any antibiotic selection. We demonstrate that an MDR ST131 strain can out-compete a commensal strain to establish intestinal colonisation in gnotobiotic mice. Furthermore, when introduced into the gut of mice pre-colonised with commensal E. coli, MDR ST131 could displace commensal E. coli from the gut to establish dominant colonisation. Displacement of the resident commensal strain occurs within 48 h of cohousing with mice colonised by MDR ST131, with ST131 becoming the dominant strain in all co-housed mice. To understand the biological process underpinning this competition, we use Biolog phenotypic microarray which identifies altered utilisation of carbon sources. Targeted genomic comparison our assayed strains reveals distinct mutational signatures. We further expand this analysis to a dataset of 19,571 genomes representing the full phylogenetic and AMR diversity of E. coli to identify a significant link between metabolism and carriage of AMR genes. We find that MDR lineages of E. coli display an increased nucleotide diversity in genes associated with carbohydrate utilisation which may afford competitive advantage for colonising the mammalian gut compared to commensal E. coli strains.

Results

Non-MDR ExPEC and MDR ExPEC are efficient colonisers of germ-free mice, with both ExPEC outcompeting a commensal isolate in co-colonisation

To determine whether MDR E. coli is able to out-compete non-MDR E. coli in the intestine in vivo, we performed competitive colonisation experiments in germ-free mice using 3 different strains of E. coli: a non-MDR (ST73) commensal strain 822-E8 isolated from a healthy human volunteer, a pathogenic non-MDR ExPEC (ST73) strain F084 isolated from a bacteraemia patient, and a pathogenic MDR ExPEC (ST131) strain F016 isolated from a bacteraemia patient (S3 Table). All 3 strains possessed an equivalent virulence-associated gene profile; however, the MDR strain F016 possessed a greater number of AMR genes (S1 and S2 Figs). Mice were inoculated with 109 colony-forming unit (CFU) of each strain via oral gavage and bacterial growth was measured by enumeration of CFU from the faeces as well as strain specific qPCR. Under these conditions, all strains could individually monocolonise germ-free mice (S3 Fig). Competitive colonisation between strains was investigated by orally gavaging GF mice with a 1:1 ratio of 2 strains in combination (see Fig 1A for combinations) followed by quantification of each strain in the faeces over the subsequent week (Fig 1B–1E). Both F084 and F016 strains out-competed the commensal 822-E8 strain achieving 96.1% and 80.7% of the total growth, respectively, by day 6 post gavage (Fig 1B–1D). Neither F084 nor the MDR F016 was able to out-compete the other with F016 accounting for 47.1% of the growth by day 6 (Fig 1B and 1E).

Fig 1. Co-colonisation of mice with 2 strains of E. coli and supernatant growth curves.

Fig 1

(A) Schematic of mouse colonisation set up, 2 strains of E. coli are mixed immediately prior to gavage. (B) Growth of E. coli in co-colonised mice measured by strain specific qPCR. Growth of the strain 2 listed in the schematic is plotted as a percentage of total growth against days post gavage (n = 5, 822-E8 and F084, growth of F084 in blue; n = 4, 822-E8 and F016, growth of F016 in orange, n = 5 F084 and F016, growth of F016 in purple). Dotted line at 50% indicating equivalent growth of both strains, values higher than 50% indicate higher growth of strain 2, while values less than 50% indicate lower growth of strain 2. (C–E) CFU per gram of faeces as measured by qPCR for mice colonised simultaneously by 822-E8 (black) and F084 (blue) (C), 822-E8 (black) and F016 (orange) (D), or F084 (blue) and F016 (orange) (E). (F–H) Growth of 822-E8 (F), F084 (G), or F016 (H) strain in 50% LB + 50% PBS (black), 822-E8 supernatant (green), F084 supernatant (blue), or F016 supernatant (orange), (n = 6). Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Raw data used to produce figures available in S1 and S2 Data.

It is possible that F084 and MDR F016 are out-competing the commensal 822-E8 strain due to phage or production of a secreted toxin. Previous data from our group has shown that an ST131 strain retards growth of both ST73 and ST10 strains in LB broth [16]. Therefore, we grew each strain in LB broth overnight, filter sterilised the spent medium before mixing in a 1:1 ratio with fresh LB, and investigated the growth kinetics of all strains in the presence of supernatant from a competing strain. No strain displayed any impairment in growth in the presence of either autologous or heterologous supernatant indicating that no strains were releasing toxins/phage to kill competing strain (Fig 1F–1H).

MDR ExPEC efficiently displaces an established commensal from the mouse intestinal tract

Next, we aimed to determine whether MDR E. coli could displace commensal E. coli that had already established a colonisation niche within the intestine. Germ-free mice were colonised with a commensal strain 822-E8 by oral gavage and colonisation allowed to stabilise for 1 week before challenging with a second E. coli strain (Fig 2A). When commensal-colonised mice were challenged with MDR strain F016, it rapidly out-competes the commensal strain 822-E8 within 4 days accounting for greater than 60% of the CFU (Fig 2B and 2C). By day 21, the MDR strain F016 accounted for 80.4% of the CFU in the faeces. In contrast, this displacement is not observed when commensal-mice colonised are challenged with the non-MDR strain F084, which results in an equilibrium of 50–50 colonisation of both strains within 4 days and remains equivalently co-colonised at 21 days post-challenge (Fig 2B and 2D). Conversely, when MDR strain F016 monocolonised mice are challenged with commensal strain 822-E8, the commensal is unable to displace F016, accounting for 20.4% of the CFU at day 4 and further diminishing to 15.3% at day 21 (Fig 2B and 2E). These results are not due to changes in commensal colonisation as growth remains stable in the control group throughout the experiment (Fig 2F). Collectively, these data demonstrate that MDR E. coli strain F016 can displace the commensal E. coli strain 822-E8 to establish itself as a dominant coloniser of the gut in vivo.

Fig 2. Mice colonised with a test strain for 1 week before challenge with a second strain.

Fig 2

(A) Schematic of displacement experiment in which mice are pre-colonised with a 109 CFU of the test strain followed a week later by a second gavage with 109 CFU of a challenge strain. (B) Growth of the challenge strain described in panel A in pre-colonised mice measured by strain specific qPCR at select time points. Data presented as percentage of total growth attributable to challenge strain (n = 5 for 822-E8 vs. F084, growth of F084 in blue, n = 4 for 822-E8 vs. F016, growth of F016 in orange, n = 4 for F016 vs. 822-E8, growth of 822-E8 in black). Vertical dotted line indicates time point for challenge with second strain. Horizontal dashed line indicates 50% corresponding to equivalent colonisation of test and challenge strains. (C–E) Growth of both colonising strains in mice measured by strain-specific qPCR, CFU calculated against a standard curve and normalised to faecal pellet weight. Growth of 822-E8 strain in black circles, growth of F084 in blue squares and growth of F016 in orange triangles. Vertical dotted line indicates time of challenge with second strain. (F) Growth of 822-E8 in colonised mice challenged with PBS. Growth measured by CFU enumeration from plates at regular intervals. Vertical dotted line indicates time of challenge with PBS. Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Raw data used to produce figure available in S3 Data.

To determine whether our findings using oral gavage (with large quantities of bacteria) could be replicated in the setting of environmental exposure to MDR E. coli, we monocolonised mice wither either commensal 822-E8 or MDR ExPEC F016. After allowing colonisation to stabilise for 7 days mice were co-housed (Fig 3A). Within 48 h, F016 is observed in the faeces of all mice and becomes the dominant coloniser in all mice by day 4 accounting for nearly 80% of the CFU (Fig 3B). This colonisation dominance is persistent and sustained for many weeks (Fig 3B). Of note, F016 monocolonised mice did acquire a low level of colonisation by 822-E8 following co-housing, but F016 remained the dominant strain with 822-E8 accounting for less than 20% of faecal CFUs. This MDR F016 phenotype is not due to strain-specific differences in inherent ability to colonise the mouse gut, as the total CFU recovered from F016 monocolonised mice is equivalent to 822-E8 monocolonised mice (Fig 3C and 3D). The host response can influence the ability of certain pathogens to establish colonisation. The host immune response in the small intestine and colon of colonised mice was analysed histologically revealing no evidence of inflammatory cell recruitment or tissue damage in response to colonisation by F016 (S5 Fig). Expression of 11 cytokines was assayed by probe-based qPCR from tissue collected from the small intestine, caecum, and colon. Expression of the assayed cytokines in the small intestine and colon revealed few differences between colonisation conditions (S6S8 Figs).

Fig 3. Transmission of strains between monocolonised mice when co-housed.

Fig 3

(A) Schematic of co-housing experiment in which mice are monocolonised with either 822-E8 or F016 strains for 1 week before exchanging mice between cages. (B) Growth of the invading strain in co-housed mice measured by strain-specific qPCR at select time points (n = 4 for 822-E8 shown in black, n = 5 for F016 shown in orange). Data presented as a percentage of total growth. (C, D) CFU per gram of faeces measured by qPCR in monocolonised mice followed by co-housing. Bacterial growth measured by strain specific qPCR from faecal pellets, 822-E8 growth (black circles) and growth of F016 (orange triangles). (C) Mice monocolonised by an 822-E8 strain (n = 4). (D) Mice monocolonised by F016 (n = 5). Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Raw data used to produce figure available in S4 Data.

Given that our displacement findings cannot be driven by classical virulence genes (S1 Fig) nor differences in host response, we sought to perform a comprehensive comparative genomic and phenotypic analysis of the E. coli strains competed in vivo to identify the factors underpinning F016’s colonisation success.

The MDR ST131 strain F016 displays altered carbon source utilisation alongside numerous polymorphisms in metabolic genes

Stains F084, F016, and 822-E8 were subject to Biolog analysis using commercially available Phenotype MicroArray plates. Significant differences were only detected in the PM1 carbon utilisation plate. Of the 96 conditions tested in PM1, 34 showed statistical (<0.05 P-value) differences between the 3 strains (Fig 4A). The data shows that the MDR strain F016 is less efficient at utilising N-Acetyl-Glucosamine, trehalose, mannose, xylose, fructose, maltose, melibiose, methyl-D-galactoside, lactose, and lactulose than strains F084 and 822-E8. Conversely, strain F016 is far more efficient at utilising keto-butyric acid, sucrose, L-glutamine, hydroxy-butyric acid, D and L-threonine, and glyoxylic acid. Additionally, both F084 and F016 were significantly more efficient at utilising both propionic and mucic acid. To investigate the genomic factors underpinning these phenotypic differences, we examined genetic polymorphisms in 73 genes associated with the metabolites above. Using the commensal 822-E8 strain as a reference revealed that there was a very low number of polymorphisms in the F084 strain, while the F016 strain displayed a far higher number of mutations. The majority of mutations were single nucleotide polymorphisms (SNPs) that caused synonymous mutations or missense mutations (Fig 4E and 4F). In addition to mutational profiling, the strains were subject to a functional pangenomic analysis. A pangenome of the 3 strains was constructed, the resulting pangenome reference file was functionally annotated using the eggNOG database with the eMapper utility. This analysis identified 712 genes uniquely present and 466 genes uniquely absent in the F016 strain. The majority of these genes were annotated with “S -function unknown” (238/712 and 98/466) alongside a significant number with no functional annotation (106/712 and 60/466). Of the uniquely present genes, the most abundant COG categories were “Replication, recombination and repair,” “Transcription,” and “Carbohydrate metabolism” with 62, 50, and 37 genes, respectively. While the uniquely absent genes were abundant with “Replication, recombination and repair,” “Cell membrane biogenesis,” and “Transcription” with 40, 39, and 25 genes, respectively. Based on phenotypic differences, we focussed on the carbon metabolism genes that were differentially present in F016 revealing that it possessed multiple genes such as sgc operon which has been putatively annotated as a sugar uptake and isomerization operon. All 3 strains possessed the fucA gene; however, F016 possessed a duplicate allele. Moreover, the F016 strain possessed scrB and scrK for sucrose metabolism, as well as mngA and mngB, which are involved in mannose uptake and utilisation.

Fig 4.

Fig 4

(A) Biolog phenotypic microarray analysis of mouse colonising strains. (B) Tajima’s D measurements of genes involved in metabolism of differentially utilised metabolites. Genes which display a different value between ST73 (blue) and ST131 (orange) are labelled. (C–H) Genes involved in utilisation of metabolites that show differential patterns between ST73 and ST131 lineages. Number of gene copies per genome in ST73 I and ST131 (D). Percentage identity of K12 reference allele in ST73 (E) and ST131 (F). Percentage coverage of reference allele in ST73 (G) and ST131 (H). (I) The proportion of the accessory pangenome annotated with G COG category (carbohydrate transport and metabolism) against the proportion of each lineage with more than 2 resistance genes. Red line indicates linear regression line (R-squared of 0.4518, P-value of 0.0007). Raw data used to produce panel A available in S5 Data. Select metabolic reference gene sequences used to produce panels B–H available at 10.6084/m9.figshare.c.6147189. Genome assemblies and bioinformatics pipeline used to produce panel I are detailed in the Methods section.

ST131 displays reduced selective pressure on select metabolic loci

To explore whether our observations could be applied to a wider selection of genomes, we downloaded assemblies for the ST73 and ST131 lineages from (S3 Table). We screened these assemblies for the 73 genes we selected from our phenotypic analysis, extracted gene sequences, and calculated a Tajima’s D value, which is a measurement of selection on a gene with values around 0 indicating an absence of selection. Comparisons between ST73 and ST131 reveal that treC, prpBRDCE, cyaY, yihU, glcB, lacA, and glnA have values closer to 0 than ST73, suggesting these alleles are under reduced selective pressures (Fig 4B). Further examination of the genes identified highlighted other differences between ST73 and ST131. Specifically, yihU is completely absent from ST73 but present in a significant number of ST131 genomes (Fig 4C and 4D). LacYZ, glcB, and prp operon genes display an elevated level of loss in ST131 (Fig 4C and 4D), with lacYZ showing partial gene loss in ST131 (Fig 4 H). While ST73 harbours a partial duplication of garD which is linked to the very high Tajima’s D value for this gene (Fig 4B, 4C, 4E and 4G). ST131 possess 2 allelic versions of treC and prpR evident as 2 identity peaks (Fig 4F). GlcB appears as 2 allelic variants in ST73 but in ST131, there is more diversity with a broader distribution of identity values (Fig 4E and 4F). Together, this data indicate that ST131 lineage is undergoing a complex evolutionary process targeting metabolic capabilities evident as duplications of core metabolic genes as well as allelic variation.

MDR lineages display an increase in genetic diversity of carbohydrate metabolism genes in their accessory pangenome associated with recombination of new variant alleles

We sought to examine whether our genomic observations of ST131 were unique or common to multiple MDR lineages of E. coli. We curated a dataset of 19,571 E. coli genome assemblies encompassing the major E. coli phylogroups (A, B1, B2, D, E, and F/G), representing 20 STs incorporating commensal, ExPEC, and EPEC/EHEC lineages (S17A Fig and S3 Table). Antibiotic resistance genes are concentrated in 5 ExPEC lineages: ST38, ST69, ST131, ST167, and ST648 (S17B Fig). These lineages have a high proportion of their population carrying multiple (>1) resistance genes (ST38: 89.0%, ST69: 80.3%, ST131: 85.7%, ST167: 99.1%, ST648: 93.5%). Pangenomes for the 20 different lineages of E. coli were constructed with Roary v3.10.2 using an identity threshold of 95%, a core gene frequency of 99% with paralog splitting disabled. This setting allows us to specifically look for unique alleles of core genes as those unique alleles then become part of the accessory genome [13]. The host generalist ST10 had the greatest pangenome size with 46,259 gene clusters identified followed by ST131 with 23,857 clusters (S4 Table and S14 Fig). Core genome size was consistent across all lineages averaging 3,777 genes (S4 Table and S15 Fig). There was no correlation between pangenome size and carriage of AMR genes (S13 Fig). Curiously, AMR carriage was significantly negatively associated with the proportion of phage in the pangenome but showed no correlation with recombination (S17C and S17D Fig). Pangenomes were functionally annotated using the eggNOG database with the eMapper utility, functional composition of the pangenome was explored using Clusters of Orthologous Groups (COG) categories. Links between AMR and biological function were explored in the core and accessory genome using linear regressions analysis that revealed a single significant association. Specifically, lineages with a higher proportion of AMR genes displayed an increased number of “Carbohydrate metabolism and transport” genes in their accessory genome (Fig 4I). There were no other significant correlations between COG categories and carriage of AMR genes after correcting for multiple testing. Our data suggest that diversification of carbohydrate metabolic genes is correlated to the acquisition of multidrug resistance in E. coli. We sought to determine the source driving our observed diversity of carbohydrate genes in AMR lineages. We then looked at the recombination plot created for the main MDR E. coli lineage ST131 (S18A Fig) and the main non-MDR ExPEC ST73 (S18B Fig). Our analysis clearly shows recombination occurring in key metabolic loci that does not occur in ST73 and that these loci house metabolism genes occurring as allelic variants in the accessory genome dataset. Together with previously published data, our genomic analysis provides compelling evidence for unique patterns of evolution in metabolism genes within MDR lineages of E. coli.

Discussion

The evolution and global transmission of AMR are a major threat to public health. Genomic identification of antibiotic resistance genes in our global dataset highlights that AMR is concentrated in a number pandemic lineages. This is most evident when examining the average number of resistance genes per genome; ST167, ST648, ST38, and ST131 all display on average in excess of 7 resistance genes per genome. This result is not driven by many resistance genes within a small subpopulation, as ST167, ST648, ST38, and ST131 all have in excess of 80% of their population possessing multiple resistance genes highlighting the success of these lineages. This observation is aligned with numerous other studies that frequently report these populations as major MDR pathogens, confirming previous observations that AMR carriage is not equal across the E. coli population with AMR being concentrated in certain lineages [2].

Successful pandemic clones must transmit from the environment to individuals or between individuals rapidly in order to spread globally. Here, we demonstrate that an MDR ST131 strain can readily colonise new hosts even when those hosts are pre-colonised with commensal E. coli. The invading ST131 becomes the dominant colonising strain in mice, both when the invading strain is introduced artificially via oral gavage and when mice are co-housed. It is important to emphasise that this transmission is occurring in the absence of any antibiotic treatment conferring a selective advantage to ST131. Typically, it has been required that mice are treated with streptomycin to allow E. coli strains to colonise them; however, more recent studies, alongside data presented here, indicate that ST131 strains do not require antibiotic treatment in order to competitively colonise mice [17]. In our study, the ST131 out-colonises another ExPEC strain of the common ST73 lineage. This implies that ST131 possesses some mechanism by which it can out-compete commensals that is lacking in another highly successful but non-MDR ExPEC lineage ST73. While our study is limited to the use of germ-free mice, our observations mimic those made from human traveller studies which have observed MDR E. coli as frequent colonisers of healthy travellers in the absence of antibiotics [79]. Within household transmission has also been observed for ST131 [18]. Studies of healthy individuals who travel to regions where antibiotic resistance is endemic have reported varying levels of colonisation of between 30% and 70% upon return [7]. Sampling travellers during their trip revealed a much higher rate of colonisation rate of 95%, of which E. coli was the most common colonising bacteria [9]. From our data, the resident commensal strain was not completely displaced, similar observations have been made of human travellers, specifically individuals colonised by MDR E. coli had a recurrence of their original commensal E. coli at the end of their travels [8].

Phenotypic microarray of our colonising strains again pointed to altered utilisation of carbon sources. Subsequent targeted genomic analysis highlighted altered mutational profiles of our assayed strains. We expanded this analysis to multiple MDR lineages of E. coli in comparison to multiple non-MDR ExPEC lineages revealing diversification of carbohydrate metabolic genes in multiple MDR lineages. The genomic signature we have identified is complex and requires further investigation. Previous pangenome analysis identified metabolic loci as being enriched in nucleotide diversity in ST131 compared to other ExPEC, specifically anaerobic metabolic genes were exhibiting increased genetic variation [13]. Our functional pangenome analysis supports these observations, revealing that there is a significant correlation between carriage of AMR genes and genetic diversity in metabolism genes. Specifically, there is increased variation in genes encoding carbohydrate metabolism in lineages with a high rate of antibiotic resistance carriage. Previous analyses have focussed on individual lineages, whereas here, we present data on multiple MDR ExPEC lineages, revealing that metabolic variation is a shared adaptation of MDR E. coli. Experimental evolution studies have identified that E. coli can evolve resistance to antibiotic stress through mutations in core metabolic genes, particularly those involved in carbon and energy metabolism [19]. These observed mutations occur at low frequency and were only detected through sequencing of multiple isolates from a population; however, they were still detectable in datasets of clinical samples demonstrating their relevance. A large-scale bacterial genetic screen to test the effect of allelic variation in key metabolism genes on the ability to colonise and displace commensal E. coli in the mammalian intestinal tract would seem attractive. However, the signal observed in our dataset occurs in multiple genes and pathways and genetically investigating such a polygenic trait is far from trivial. We suggest further investigation of our findings will need to combine classical genetics with long-term and complex experimental studies attempting to recapitulate MDR clone evolution.

Collectively, our data demonstrate that MDR E. coli is highly capable of host intestinal colonisation, displacing resident commensal E. coli to become the dominant strain and readily transmitting between hosts. Our genomic analysis implicates metabolism as a pivotal factor in the evolution of AMR linked to the incredible gut colonisation ability of MDR E. coli.

Methods

Ethics statement

Animal protocols were reviewed and approved by the University of Calgary Animal Care Committee (approved protocol numbers AC17-0090 and AC19-0139) and animal experiments were conducted in accordance with Canadian Council on Animal Care guidelines.

Mouse colonisation

Mouse colonisation experiments were conducted at the International Microbiome Centre, University of Calgary, Canada. Germ-free mice were bred and maintained in flexible film isolators in our axenic breeding facility, and germ-free status was confirmed by a combination of Gram staining, Sytox green DNA staining, anaerobic and aerobic culture, and 16S rRNA gene amplicon sequencing from faeces were maintained in isocages in our gnotobiotic facility. Germ-free C57BL/6 mice were colonised with 109 CFU of bacteria via oral gavage (see S3 Table and S4 and S5 Figs for details of strains used for colonisation) and maintained in sterile isocages in our gnotobiotic facility throughout the duration of experiments. Bacterial colonisation was monitored by CFU enumeration on UTI Chromogenic Agar (Thermo) from faecal pellets as well as by DNA extraction and strain-specific probe-based qPCR. DNA from faecal pellets was extracted using the MagMAX Microbiome Ultra Nucleic Acid isolation kit (Thermo) on a KingFisher Flex instrument (Thermo) following manufacturer’s instructions. Strain-specific primers and probes were designed to target unique genes (822-E8: clpP, F084: lon, F016: prtRS4 Table) identified from genome data. Probes were manufactured by Integrated DNA Technologies (IDT). Reactions were performed using PrimeTime Gene Expression master mix (IDT) on a QuantStudio 1 system (Thermo). Reactions were performed following manufacturer’s recommended parameters: 3 min at 95*C, 40 cycles of 15 s at 95*C, 1 min at 60*C, fluorescence readings taken at the end of the extension stage. A standard curve was generated from a bacterial culture of known CFU.

In vitro supernatant cultures

Bacteria were grown in LB broth to an OD600 of between 0.4 and 0.6, cultures were pelleted at 4,000 rpm for 15 min. The supernatant was passed through a 0.22 μm filter, the filtrate was diluted in a 1 to 1 ratio with fresh LB. Bacteria were inoculated into the supernatant mixture and grown in a 96-well plate at 37°C with growth measured by OD600 readings at 10-min intervals by a Spark Microplate Reader (Tecan).

Functional metabolic analysis

Strains (F084, F016, and 822 E8) were grown on LB-NaCl agar (5 g/L Yeast Extract (Melford, Y20020-500.0), tryptone 10 g/L (Melford, T60060-500.0), and agar (Melford, A20020-500.0)) for 16 h. Inoculations were set up following manufacturer’s instructions with below modifications. Biomass was removed with a cell scraper and suspended in inoculation fluid 0a (IF-0a –Techno-path, 72268—PM IF-0a GN/GP Base (1.2×) 125 ml) to an O.D.600 of 0.185 +/− 0.05. This was then diluted 1:6 with IF-0a containing 1.4% (v/v) of Biolog Redox Dye Mix A (100×, Techno-path, 74221). To each well of each PM1 plate (Techno-path, 12111), 100 μl of this suspension was added and strains incubated for up to 48 h at 37°C, static, in a OmniLog PM system (imaging every 15 min). Data was extracted using Biolog softwares (conversion of D5E to OKA: D5E_OKA Data File Converter v1.1.1.15 and extraction of raw kinetic data using PM analysis software: Kinetic V1.3). Statistically relevant results were identified using a one-way ANOVA with a P-value threshold of 0.05.

Genomic dataset curation, pangenome construction, and AMR gene detection

A total of 20 lineages or sequence types (STs) were selected from the literature with a focus on ExPEC lineages but also including EHEC and EPEC clones. This resulted in a dataset of 19,571 E. coli genome sequences encompassing all the E. coli phylogroups (A, B1, B2, D, E, and F/G) (S1 and S2 Tables) [10.6084/m9.figshare.c.6147189]. The earliest samples with reliable metadata were from 1980; however, the majority was sequenced in recent decades. Humans represented the major source niche for all lineages except ST117 for which poultry was the major niche. This dataset contained samples from multiple countries; however, Europe and North America accounted for the majority.

Genome assemblies for each lineage were downloaded from Enterobase [20] using a custom python script [https://github.com/C-Connor/EnterobaseGenomeAssemblyDownload]. Duplicated assemblies were identified using Mash v1.1.1 [21] to estimate genome similarity, a custom R script then removed isolates with a Mash distance of 0 [https://github.com/C-Connor/MashDistDeReplication]. Dendrograms of Mash distances were also constructed and examined for outlier genomes that were not part of a larger cluster. The remaining genome files were annotated with Prokka v1.12 [22] and pangenomes were constructed with Roary v3.10.2 [23] using a 95% identity threshold, a 99% core genome threshold, paralog splitting was disabled, and a core genome alignment was produced using MAFFT. AMR genes were detected using Abricate v 0.8 [https://github.com/tseemann/abricate] with the Resfinder-2018 database [24], results were filtered to remove hits with less than 80% resistance gene coverage. A phylogeny of the whole dataset was constructed using MashTree v0.36.2 [25] and visualised in iTOL [26].

Targeted genomic comparisons

Genes of interest were selected based on their involvement in the utilisation of Biolog metabolites. Short read data for F084 and F016 strains was mapped to the commensal 822-E8 strain using Snippy 4.6.0 (https://github.com/tseemann/snippy). Reference gene sequences from (K12 MG1655 U00096.3) were downloaded from NCBI and genome assemblies were screened using Abricate. Gene seqeuences were extracted from each assembly using extract_genes_ABRricate.py (https://github.com/boasvdp/extract_genes_ABRicate). Sequences were aligned with MAFFT 7.487 using default parameters. Tajima’s D measurements from the alignments were calculated in R using the packages ape 5.7.1 39 and pegas 1.2

Pangenome functional annotation

Pangenome reference Fasta files produced by Roary were functionally annotated using emapper-1.0.3-3-g3e22728 [27] based on eggNOG orthology data [28]. Sequence searches were performed using DIAMOND [29]. Functional annotation data was combined with the gene presence absence matrix and analysed in R v4.0.3. To examine if there was any association between functional composition of the accessory pangenome or core genome linear regression was performed between carriage of AMR (as a proportion of the population with 2 or more AMR genes) and individual COG categories, correcting for multiple testing.

Supporting information

S1 Method. Supplementary methodology for histological and cytokine analysis of mouse tissues.

(DOCX)

S1 Table. Details of E. coli strains used for mouse colonisation and Biolog experiments.

(XLSX)

S2 Table. Primers and probes used for CFU quantification qPCR and cytokine qPCR.

(XLSX)

S3 Table. Numbers of E. coli genomes from Enterobase analysed.

(XLSX)

S4 Table. Pangenome size of each E. coli lineage analysed.

(XLSX)

S1 Fig. Heatmap of virulence factors identified in mouse colonising strains.

(EPS)

S2 Fig. Heatmap of AMR genes identified in mouse colonising strains.

(EPS)

S3 Fig. CFU of colonising bacteria in monocolonised mice measured by enumeration from UTI Chromogenic agar plates.

CFU counts were adjusted to faecal pellet weight. Geometric average CFU of 822-E8 (black line), F084 (blue line), and F016 (orange line) is shown with geometric standard deviation, 3 replicates for each condition. Raw data used to produce figure available in S6 Data.

(EPS)

S4 Fig. Inflammatory histology score for sections of small intestine and colon from colonised mice and germ-free control mice.

Small intestine histology scores for monocolonised mice (A), co-incolucated/competitive colonisation mice (B), and monocolonised mice challenged with a second strain after 1 week (C). Colon section histology scores for monocolonised mice (D), co-incolucated/competitive colonisation mice (E), and monocolonised mice challenged with a second strain after 1 week (F). Scores were assigned to inflammatory cell infiltrate (black circles), changes to epithelium (green squares) and overall mucosal architecture (blue triangles). Score of 1 indicates homeostatic mucosa while a score of 5 indicates severe inflammatory disruption. Points represent scores for individual fields of view (FoV) taken from multiple tissue sections. Raw data used to produce figure available in S7 Data.

(EPS)

S5 Fig. Representative histological sections of colonised mouse small intestine and colon stained with HE, 100 μm scale bar.

Germ-free control mice are included.

(EPS)

S6 Fig

Cytokine expression in the small intestine (A), caecum (B), and colon (C) of monocolonised mice 3 weeks after colonisation. Mice were colonised with a 822-E8 (black), F084 (blue), or F016 (orange). Germ-free mice were also assayed (open circles). Expression of cytokines is displayed as the delta Ct between cytokine and housekeeping gene Pol2ra, negative values indicate lower expression than housekeeping gene. Statistical significance determined with 2-way ANOVA with Tukey’s multiple comparisons, n = 3 for all conditions. Raw data used to produce figure available in S8 Data.

(EPS)

S7 Fig

Cytokine expression in the small intestine (A), caecum (B), and colon (C) of co-inoculated mice 1 week after colonisation. Mice were colonised with an 822-E8 and F084 (blue, n = 5), 822-E8 and F016 (orange, n = 4), or F084 and F016 (purple, n = 5). Germ-free mice were also assayed (open circles, n = 3). Expression of cytokines is displayed as the delta Ct between cytokine and housekeeping gene Pol2ra, negative values indicate lower expression than housekeeping gene. Statistical significance determined with 2-way ANOVA with Tukey’s multiple comparisons. Raw data used to produce figure available in S9 Data.

(EPS)

S8 Fig

Cytokine expression in the small intestine (A), caecum (B), and colon (C) of monocolonised mice which were challenged with a second strain 7 days after initial colonisation. Mice were colonised with 822-E8 and challenged with PBS (pink, n = 5), 822-E8 challenged with F084 (blue, n = 5), 822-E8 challenged with F016 (orange, n = 4), or F016 challenged with 822-E8 (black, n = 4). Germ-free mice were also assayed (open circles, n = 3). Expression of cytokines is displayed as the delta Ct between cytokine and housekeeping gene Pol2ra, negative values indicate lower expression than housekeeping gene. Statistical significance determined with 2-way ANOVA with Tukey’s multiple comparisons. Raw data used to produce figure available in S10 Data.

(EPS)

S9 Fig. Cycle threshold values for strain-specific probes assayed using DNA extracted from faecal pellets from monocolonised mice; 822-E8 specific probe (clpP) in blue, F084 specific probe (lon) in green, and F016 specific probe (prtR) in orange.

Raw data used to produce figure available in S11 Data.

(EPS)

S10 Fig. Standard curves for CFU determination.

DNA isolates from broth culture of known CFU serially 10-fold diluted and plotted against Ct for that dilution. Colour lines indicate standard curve from stock dilutions, while black lines indicate standard curves from every assay plate used for CFU quantitation. Standard curves for 822-E8 specific probe clpP (A), F084 probe lon (B), and F016 probe prtR (C). Raw data used to produce figure available in S12 Data.

(EPS)

S11 Fig

Source niche for genome in dataset (A) and cumulative time of collection (B). Metadata used to produce figure available at 10.6084/m9.figshare.c.6147189.

(EPS)

S12 Fig. Geographic distribution of genomes in dataset, colour scale is logarithmic.

Figure was produced in R using ggplot2 (https://ggplot2.tidyverse.org) with a map layer from Natural Earth (https://www.naturalearthdata.com/). Metadata used to produce figure available at 10.6084/m9.figshare.c.6147189.

(EPS)

S13 Fig

Correlation between pangenome size and average number of resistance genes (A). Correlation between pangenome size and proportion of the lineage with 2 or more resistance genes (B).

(EPS)

S14 Fig. Pangenome rarefaction curves for the accessory compartment of each ST pangenome.

(EPS)

S15 Fig. Core genome rarefaction curves for each ST.

(EPS)

S16 Fig

Pangenome total size against the proportion of genes annotated as hypothetical proteins for each ST (A). Pangenome total size against the proportion of the pangenome assigned a COG category for each ST (B).

(EPS)

S17 Fig. Phylogenetic tree of selected lineages of E. coli, incidence of AMR genes within the dataset and correlations between HGT and AMR gene content.

(A) Phylogenetic tree of dataset produced from Mash distances, tip branches are coloured by ST and phylogroups are outlined. (B) The proportion of the lineage with 2 or more resistance genes of any class against the proportion of the lineage with 1 or more beta-lactamase gene. (C) Proportion of the pangenome that is associated with phage elements against the proportion of the lineage that has 2 or more resistance genes of any class. (D) Proportion of the genome predicted to be within a recombination block against the proportion of the lineage that has 2 or more resistance genes of any class. Red lines indicate linear regressions (B: R2 0.954, P-value 1.61 × 10−13 C: R2 0.369, P-value 0.0045, D: R2 0.138, P-value 0.117).

(EPS)

S18 Fig

Recombination regions predicted by Gubbins in ST73 (A) and ST131 (B) lineages. Red blocks indicate putative regions of recombination. Yellow and orange track bar indicate position in reference genome. Select regions are annotated.

(PDF)

S1 Data. Colony forming units from co-inoculated mice as measured by ST-specific qPCR.

Data used to produce Fig 1B–1E.

(XLSX)

S2 Data. Growth curves of strains used to colonise mouse in culture supernatant from competing strains.

Data used to produce Fig 1F–1H.

(XLSX)

S3 Data. Colony forming units from colonised mice with subsequent challenge as measured by ST-specific qPCR.

Data used to produce Fig 2B–2F.

(XLSX)

S4 Data. Colony forming units from co-housed mice with as measured by ST-specific qPCR.

Data used to produce Fig 3B–3D.

(XLSX)

S5 Data. Biolog phenotypic microarray data for plate PM1.

Data used to produce Fig 4A.

(XLSX)

S6 Data. Colony forming units from mice colonised by a single strain measured by plating.

Data used to produce S3 Fig.

(XLSX)

S7 Data. Inflammatory scoring for histological sections of mouse small intestine and colon.

Data used to produce S4 Fig.

(XLSX)

S8 Data. Expression of a panel of cytokines in the small intestine, caecum, or colon of mice colonised by a single strains, measured by qPCR.

Data used to produce S6 Fig.

(XLSX)

S9 Data. Expression of a panel of cytokines in the small intestine, caecum, or colon of mice co-inoculated with 2 strains, measured by qPCR.

Data used to produce S7 Fig.

(XLSX)

S10 Data. Expression of a panel of cytokines in the small intestine, caecum, or colon of mice pre-colonised with subsequent challenge, measured by qPCR.

Data used to produce S8 Fig.

(XLSX)

S11 Data. Cross reactivity of ST-specific probes.

Data used to produce S9 Fig.

(XLSX)

S12 Data. Standard curves for ST-specific probes used to quantify CFU.

Data used to produce S10 Fig.

(XLSX)

Abbreviations

AMR

antimicrobial resistance

CFU

colony-forming unit

ESBL

extended spectrum beta-lactamase

ExPEC

extra intestinal pathogenic Escherichia coli

IDT

Integrated DNA Technologies

MDR

multidrug resistance

SNP

single nucleotide polymorphism

ST

sequence type

Data Availability

All relevant data are within the paper and its Supporting Information files. All genomic data used in this study can be found in a dedicated figshare repository 10.6084/m9.figshare.c.6147189.

Funding Statement

This work was funded by a Wellcome Trust funded MIDAS PhD studentship awarded to CC (Grant number 203821/Z/16/A). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Poirel L, Madec J-Y, Lupo A, Schink A-K, Kieffer N, Nordmann P, et al. Antimicrobial Resistance in Escherichia coli. Microbiol Spectr. 2018;6. doi: 10.1128/microbiolspec.ARBA-0026-2017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Dunn SJ, Connor C, McNally A. The evolution and transmission of multi-drug resistant Escherichia coli and Klebsiella pneumoniae: the complexity of clones and plasmids. Curr Opin Microbiol. 2019;51:51–56. [DOI] [PubMed] [Google Scholar]
  • 3.Denamur E, Clermont O, Bonacorsi S, Gordon D. The population genetics of pathogenic Escherichia coli. Nat Rev Microbiol. 2021;19:37–54. [DOI] [PubMed] [Google Scholar]
  • 4.Kallonen T, Brodrick HJ, Harris SR, Corander J, Brown NM, Martin V, et al. Systematic longitudinal survey of invasive Escherichia coli in England demonstrates a stable population structure only transiently disturbed by the emergence of ST131. Genome Res. 2017. doi: 10.1101/gr.216606.116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Gladstone RA, McNally A, Pöntinen AK, Tonkin-Hill G, Lees JA, Skytén K, et al. Emergence and dissemination of antimicrobial resistance in Escherichia coli causing bloodstream infections in Norway in 2002–17: a nationwide, longitudinal, microbial population genomic study. Lancet Microbe. 2021;2:e331–e341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Banerjee R, Johnson JR. A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131. Antimicrob Agents Chemother. 2014;58:4997–5004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Arcilla MS, van Hattem JM, Haverkate MR, Bootsma MCJ, van Genderen PJJ, Goorhuis A, et al. Import and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a prospective, multicentre cohort study. Lancet Infect Dis. 2017;17:78–85. [DOI] [PubMed] [Google Scholar]
  • 8.Bevan ER, McNally A, Thomas CM, Piddock LJV, Hawkey PM. Acquisition and Loss of CTX-M-Producing and Non-Producing Escherichia coli in the Fecal Microbiome of Travelers to South Asia. MBio. 2018;9. doi: 10.1128/mBio.02408-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kantele A, Kuenzli E, Dunn SJ, Dance DAB, Newton PN, Davong V, et al. Dynamics of intestinal multidrug-resistant bacteria colonisation contracted by visitors to a high-endemic setting: a prospective, daily, real-time sampling study. Lancet Microbe. 2021;2:e151–e158. doi: 10.1016/S2666-5247(20)30224-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Davies M, Galazzo G, van Hattem JM, Arcilla MS, Melles DC, de Jong MD, et al. Enterobacteriaceae and Bacteroidaceae provide resistance to travel-associated intestinal colonization by multi-drug resistant Escherichia coli. Gut Microbes. 2022;14:e2060676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.McNally A, Oren Y, Kelly D, Pascoe B, Dunn S, Sreecharan T, et al. Combined Analysis of Variation in Core, Accessory and Regulatory Genome Regions Provides a Super-Resolution View into the Evolution of Bacterial Populations. PLoS Genet. 2016;12:e1006280. doi: 10.1371/journal.pgen.1006280 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zong Z, Fenn S, Connor C, Feng Y, McNally A. Complete genomic characterization of two Escherichia coli lineages responsible for a cluster of carbapenem-resistant infections in a Chinese hospital. J Antimicrob Chemother. 2018;73:2340–2346. [DOI] [PubMed] [Google Scholar]
  • 13.McNally A, Kallonen T, Connor C, Abudahab K, Aanensen DM, Horner C, et al. Diversification of Colonization Factors in a Multidrug-Resistant Escherichia coli Lineage Evolving under Negative Frequency-Dependent Selection. MBio. 2019;10:e00644–e00619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Schaufler K, Semmler T, Wieler LH, Trott DJ, Pitout J, Peirano G, et al. Genomic and Functional Analysis of Emerging Virulent and Multidrug-Resistant Escherichia coli Lineage Sequence Type 648. Antimicrob Agents Chemother. 2019;63:e00243–e00219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Feng Y, Liu L, Lin J, Ma K, Long H, Wei L, et al. Key evolutionary events in the emergence of a globally disseminated, carbapenem resistant clone in the Escherichia coli ST410 lineage. Commun Biol. 2019;2:322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Cummins EA, Moran RA, Snaith AE, Hall RJ, Connor CH, Dunn SJ, et al. Loss of type VI secretion systems in multi-drug resistant Escherichia coli clones. bioRxiv. doi: 10.1101/2023.03.28.534550 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Sarkar S, Hutton ML, Vagenas D, Ruter R, Schüller S, Lyras D, et al. Intestinal Colonization Traits of Pandemic Multidrug-Resistant Escherichia coli ST131. J Infect Dis. 2018;218:979–990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Johnson JR, Clabots C, Kuskowski MA. Multiple-host sharing, long-term persistence, and virulence of Escherichia coli clones from human and animal household members. J Clin Microbiol. 2008;46:4078–4082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lopatkin AJ, Bening SC, Manson AL, Stokes JM, Kohanski MA, Badran AH, et al. Clinically relevant mutations in core metabolic genes confer antibiotic resistance. Science. 2021;371:eaba0862. doi: 10.1126/science.aba0862 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Zhou Z, Alikhan N-F, Mohamed K, Fan Y, Achtman M. The EnteroBase user’s guide, with case studies on Salmonella transmissions, Yersinia pestis phylogeny, and Escherichia core genomic diversity. Genome Res. 2020;30:138–152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ondov BD, Treangen TJ, Melsted P, Mallonee AB, Bergman NH, Koren S, et al. Mash: fast genome and metagenome distance estimation using MinHash. Genome Biol. 2016;17:132. doi: 10.1186/s13059-016-0997-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30:2068–2069. doi: 10.1093/bioinformatics/btu153 [DOI] [PubMed] [Google Scholar]
  • 23.Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, et al. Roary: rapid large-scale prokaryote pan genome analysis. Bioinformatics. 2015;31:3691–3693. doi: 10.1093/bioinformatics/btv421 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother. 2012;67:2640–2644. doi: 10.1093/jac/dks261 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Katz LS, Griswold T, Morrison SS, Caravas JA, Zhang S, den Bakker HC, et al. Mashtree: a rapid comparison of whole genome sequence files. J Open Source Softw. 2019;4:doi: 10.21105/joss.01762 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Letunic I, Bork P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree display and annotation. Nucleic Acids Res. 2021;49:W293–W296. doi: 10.1093/nar/gkab301 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Huerta-Cepas J, Forslund K, Coelho LP, Szklarczyk D, Jensen LJ, von Mering C, et al. Fast Genome-Wide Functional Annotation through Orthology Assignment by eggNOG-Mapper. Mol Biol Evol. 2017;34:2115–2122. doi: 10.1093/molbev/msx148 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Huerta-Cepas J, Szklarczyk D, Forslund K, Cook H, Heller D, Walter MC, et al. eggNOG 4.5: a hierarchical orthology framework with improved functional annotations for eukaryotic, prokaryotic and viral sequences. Nucleic Acids Res. 2015;44:D286–D293. doi: 10.1093/nar/gkv1248 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Buchfink B, Xie C, Huson DH. Fast and sensitive protein alignment using DIAMOND. Nat Methods. 2015;12:59–60. doi: 10.1038/nmeth.3176 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Paula Jauregui, PhD

2 Dec 2022

Dear Alan,

Thank you for submitting your manuscript entitled "Multi-drug resistant E. coli displace commensal E. coli from the intestinal tract, a trait associated with elevated levels of genetic diversity in carbohydrate metabolism genes" for consideration by PLOS Biology.

As previously discussed, we would be happy to send it for peer-review as a Discovery Report (please choose this article type when finalising your submission).

Before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. After your manuscript has passed the checks it will be sent out for review. To provide the metadata for your submission, please Login to Editorial Manager (https://www.editorialmanager.com/pbiology) within two working days, i.e. by Dec 04 2022 11:59PM.

If your manuscript has been previously peer-reviewed at another journal, PLOS Biology is willing to work with those reviews in order to avoid re-starting the process. Submission of the previous reviews is entirely optional and our ability to use them effectively will depend on the willingness of the previous journal to confirm the content of the reports and share the reviewer identities. Please note that we reserve the right to invite additional reviewers if we consider that additional/independent reviewers are needed, although we aim to avoid this as far as possible. In our experience, working with previous reviews does save time.

If you would like us to consider previous reviewer reports, please edit your cover letter to let us know and include the name of the journal where the work was previously considered and the manuscript ID it was given. In addition, please upload a response to the reviews as a 'Prior Peer Review' file type, which should include the reports in full and a point-by-point reply detailing how you have or plan to address the reviewers' concerns.

Feel free to email us at plosbiology@plos.org if you have any queries relating to your submission.

Kind regards,

Nonia

Nonia Pariente, PhD

Editor in Chief

PLOS Biology

npariente@plos.org

Decision Letter 1

Paula Jauregui, PhD

6 Feb 2023

Dear Dr. McNally,

Thank you for your patience while your manuscript "Multi-drug resistant E. coli displace commensal E. coli from the intestinal tract, a trait associated with elevated levels of genetic diversity in carbohydrate metabolism genes." was peer-reviewed at PLOS Biology. It has now been evaluated by the PLOS Biology editors, an Academic Editor with relevant expertise, and by several independent reviewers.

In light of the reviews, which you will find at the end of this email, we would like to invite you to revise the work to thoroughly address the reviewers' reports.

As you will see below, all the reviewers find the manuscript interesting. However, they all think that your claims are too general or your conclusions regarding the carbohydrate metabolism are not totally convincing for a Discovery Report format. The reviewers ask to expand this point and add more mechanistic insights. We can consider the manuscript as a Research Article and we think that the manuscript will improve if you add cause-and-effect experiments and mechanistic insights.

Given the extent of revision needed, we cannot make a decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is likely to be sent for further evaluation by all or a subset of the reviewers.

We expect to receive your revised manuscript within 3 months. Please email us (plosbiology@plos.org) if you have any questions or concerns, or would like to request an extension.

At this stage, your manuscript remains formally under active consideration at our journal; please notify us by email if you do not intend to submit a revision so that we may withdraw it.

**IMPORTANT - SUBMITTING YOUR REVISION**

Your revisions should address the specific points made by each reviewer. Please submit the following files along with your revised manuscript:

1. A 'Response to Reviewers' file - this should detail your responses to the editorial requests, present a point-by-point response to all of the reviewers' comments, and indicate the changes made to the manuscript.

*NOTE: In your point-by-point response to the reviewers, please provide the full context of each review. Do not selectively quote paragraphs or sentences to reply to. The entire set of reviewer comments should be present in full and each specific point should be responded to individually, point by point.

You should also cite any additional relevant literature that has been published since the original submission and mention any additional citations in your response.

2. In addition to a clean copy of the manuscript, please also upload a 'track-changes' version of your manuscript that specifies the edits made. This should be uploaded as a "Revised Article with Changes Highlighted" file type.

*Re-submission Checklist*

When you are ready to resubmit your revised manuscript, please refer to this re-submission checklist: https://plos.io/Biology_Checklist

To submit a revised version of your manuscript, please go to https://www.editorialmanager.com/pbiology/ and log in as an Author. Click the link labelled 'Submissions Needing Revision' where you will find your submission record.

Please make sure to read the following important policies and guidelines while preparing your revision:

*Published Peer Review*

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details:

https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/

*PLOS Data Policy*

Please note that as a condition of publication PLOS' data policy (http://journals.plos.org/plosbiology/s/data-availability) requires that you make available all data used to draw the conclusions arrived at in your manuscript. If you have not already done so, you must include any data used in your manuscript either in appropriate repositories, within the body of the manuscript, or as supporting information (N.B. this includes any numerical values that were used to generate graphs, histograms etc.). For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5

*Blot and Gel Data Policy*

We require the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article's figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare them now, if you have not already uploaded them. Please carefully read our guidelines for how to prepare and upload this data: https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements

*Protocols deposition*

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Thank you again for your submission to our journal. We hope that our editorial process has been constructive thus far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Paula

---

Paula Jauregui, PhD,

Senior Editor

PLOS Biology

pjaureguionieva@plos.org

------------------------------------

REVIEWS:

Reviewer #1: Microbiome.

Reviewer #2: Maria Hadjifrangiskou. E. coli biology and host interaction.

Reviewer #3: Bacterial growth and interactions.

Reviewer #1: In the manuscript „Multi-drug resistant E. coli displace commensal E. coli from the intestinal tract, a trait associated with elevated levels of genetic diversity in carbohydrate metabolism genes" Connor and colleagues combine colonization experiments in germfree mice and bioinformatical analyses to study niche competition between three E. coli strains in the gut. They demonstrate that the tested MDR ST131 strain can reduce colonization levels of a non-MDR ST73 strain by approximately a factor of 5 in absence of antibiotic selection and in different colonization settings. Bioinformatical analysis performed by the authors show an association between AMR genes and genes involved in carbohydrate utilization in ExPEC, which leads the authors to suggest that the displacement of commensal E. colis from the gut by MDR E. coli ST131 could be mediated by carbohydrate competition and a fitness advantage of MDR E. coli strains.

Major comments: (specific comments follow below)

1. While the utilized germfree model is very simplistic and allows in vivo comparison of direct competition, I have my doubts how general the conclusions are in light of recent studies showing that commensal bacteria beyond the family Enterobacteriaceae contribute to competition between related bacteria in the gut (Eberl et al, Cell Host Microbe 2021 and Osbelt et al. Cell Host Microbe 2021). Moreover, in germfree mice, many colonization relevant carbohydrates are not released from dietary polysaccharides.

2. Very little evidence is provided that competition for carbohydrates and not differences in the ability to acquire other growth limiting factors such as amino acids and trace elements or the ability to utilize redox acceptors contribute to the competition in vivo. Therefore, how are the two analysis linked to each other?

3. The hypothesis of the authors are highly relevant, but they generalize their observations too much. Single strains are tested, which limits the conclusions that can be drawn. I would suggest that the authors should make this much clearer by referring to strains rather the STs throughout the different sections of the manuscript, including the abstract, results, and discussion.

Specific comments:

Line 142: should be "16S rRNA" There is also a sentence fragment in that line.

Line 227ff: Make sure to refer to specific strains rather than STs. In general, throughout the whole study, just one strain was used per condition (MDR, non-MDR, commensal). To see whether the effect is strain specific or if it's a general phenotype that MDR ExPEC strains outcompete commensal strains, experiments should be repeated with different strains of each category.

Line 229ff: In general the authors do not give a comprehensive description of the strains… Also, if carbohydrate utilization is the key factor, why do not test growth in different carbon sources for those three strains? What are the differences in carbohydrate preferences? Can they equally grow in important sugars available in the gut of mice (e.g sucrose, glucose, cellobiose etc.). The statement of "carbohydrate utilization" is subsequently very broad and not really followed on in the whole study? By growing strains in different media and monitoring the general carbohydrate utilization capability, it would be at least possible to identify a group of potential candidate sugars.

Line 239f: Data shown in FigS3 shows the colonization levels of a mono-colonization with the strains. This data shows, that the MDR ExPEC strain shows 5-10 fold higher colonization levels in germfree mice at day 1-5. This could influence the following phenotypes. Could strains with similar colonization levels be used? If no extra experiments are performed, please discuss this limitation.

Line 241ff: It is interesting that apparently the strains do replace each other in the gut. What happens in a defined community of strains? It is rather unlikely that travelers harbor no community in the gut when acquiring new E. coli strains. Is this working in a similar manner, when mice with low or high complex communities are used? E.g. are the E. coli strains naturally colonizing the mice from different vendors also replaced by the superior E. coli strains?

Line 248 ff. Are the strains predicted to be capable to produce toxins and phages? If so, is LB a sufficient medium to induce lytic prophage induction and release of toxins? In other enterobacterial species, toxin production is tightly regulated (e.g induction for specific substrates like sugar or iron). I would suggest, to include other modified media to exclude that toxins or phages are relevant.

If the MDR strains encode lytic prophages, it would be a clearer experiment to generate phage deficient strains and test, whether those strains fail to replace the commensal strain in vivo. Also, plaque-formation in the commensal bacteria with intestinal content of MDR-colonized could be evaluated to see whether in vivo something different happens.

In a similar direction: what happens, if strains are co-cultured in minimal media with different carbon sources? Do strains co-exist or is the commensal strain equally outcompeted? It would be at least crucial to prove in simplified in vitro experiments that the strains do outcompete each other for different substrates.

Line 293ff: : The data are largely descriptive, and none of the observations is followed on mechanistically. The mice used in this study are raised germfree, so its absolutely obvious that challenge with any kind of bacteria will stimulate the immune system. Different cytokines were measured to "assess host mucosal immune response" and the author claim relatively few differences between colonization conditions. Does that mean, that the immune response is dispensable? I don't understand, why this data are included in the manuscript. If the focus is shifted to potential differences in the immune system, the authors should provide more detailed data than one histology picture and levels of 11 cytokines.

Specifically, line 307ff "Collectively, these data demonstrate that displacement of commensal E. coli and dominant colonization by MDR ExPEC is associated with a distinct host mucosal immune response."

I think, the few data on cytokine profiles do not support a statement like this…

Line 355ff: The authors identify an "increased number of carbohydrate metabolism and transport" genes.

Does this translate in an increased ability of the MDR strains to utilize different carbohydrates? I suggest analyzing the three isolates using the Biolog Screening System to verify that the MDR strains indeed utilize a more diverse set of carbohydrates.

Where specific carbohydrates identified as being most prominent in MDR strains? Are these carbohydrate utilization genes relevant in the mouse intestine?

What happens when carbohydrate levels are increased in the mouse gut? If the carbohydrate utilization is the major factor of intraspecies competition, an increased amount of carbohydrates available in the mouse gut should impact the phenotype. This could be done by a supplementation with specific csrbohydrates, e.g., ones that are well/solely utilized by the commensal strains.

Reviewer #2: This is a compelling study that begins to investigate how ExPEC MDR isolates behave in the host compared to non-MDR isolates. The study is significant because it begins to add a much needed layer of better understanding the physiology of these pathogens as opposed to merely looking at genomic content.

I have a few questions/comments for the authors to consider:

1) The concept of altered metabolism is extremely interesting, but not discussed or expanded at all in the current study. This results section should be expanded and validated. Are there specific metabolism gene in CHO metabolism that are different? Are there more of them? What if a subset was transplanted to a non-MDR ExPEC strain? I may have missed this, but if the analysis was confined to the ExPECs, would this difference in metabolic gene carriage still be the same.

2) Gnotobiotic mouse experiment: If the MDR strain is cured (to create an isogenic non-MDR clone), would the advantage persist? These studies are elegant, but may be worth repeating in a conventionally reared mouse strain that lacks Enterobacteriaceae to observe the interaction of the strains with the rest of the microbiota. finally, given the emphasis on ExPEC, the authors should evaluate transition of the strains to the bladder by performing longitudinal urinalysis. It would be very interesting to see if the MDR strain outcompetes in transmission as well.

Reviewer #3: In the manuscript by Connor et al., the authors use a gnotobiotic mouse model to demonstrate that an MDR E. coli strain is capable of out-competing and also of displacing non-MDR E. coli from the gut. This result is interesting since it does not require antibiotics, indicating that the MDR strain has some adaptation that increases its fitness. This part of the manuscript is generally convincing, although I do have some questions that I outline below. However, the rest of the manuscript seems preliminary, because they rely on a bioinformatic analysis that is not particularly convincing - it seems to rest on a single correlation with increased diversity of carbohydrate metabolism genes, when they have yet to prove that the fitness results are general and also they do not pursue any of the hypotheses of this correlation. Thus, while I found the initial result intriguing, the paper did little to dig into the mechanism underlying this observation, and hence the observation itself seems undercapitalized on. Indeed, the manuscript suffers throughout from the lack of follow up or misinterpretation of observations. Moreover, the metabolic hypothesis is not consistent with the rest of their data, as I discuss below.

Major comments:

- Line 246: I was surprised that the ExPEC strains coexisted for 6 days, since I assume there are substantial differences. The authors should discuss the genomic differences between these two strains.

- Line 253: the growth curves in 1F-H do not rule out toxins or phage. Phage in particular are likely to be produced in times of stress that may not be mimicked by the in vitro growth environment but are present in the gut. Thus, more experiments are needed or this statement needs to be toned down a lot.

- Why could the non-MDR ExPEC strain not displace? This also seems like a worthy subject of at least discussion based on genomic content, and provides the substrate to generate candidates for knockout study in the MDR strain.

- Line 288: I don't see why the CFU equivalency means growth rate is the same.

- Line 303: I don't understand why the hypothesis of carbohydrate metabolism would lead to the prediction of cytokine response and inflammation, as they observe?

- Moreover, why is the inflammatory response only with gavage? Seems like it is something to do with initial colonization and adaptation. And if it only appears with gavage, seems like it is much less relevant to the typical human scenario, since we are not really gavaged with large quantities of pathogen.

- Line 336: the statement that AMR lineages are more recombinogenic but to the exclusion of phage seems to be implying much more mechanism than the correlation merits. Could easily be an indirect correlation. Also I don't see why it would be the proportion that matters - likely there is one or a few genes that enables metabolism of particular aspects of the diet that causes the fitness advantage in their strain.

- Most of all, while I find the association of fitness with carbohydrate metabolism interesting, it is in some sense expected since previous evolution experiments in mice have shown that E. coli evolves by selecting for carb metabolism genes. Moreover, basing it on the correlation in Fig. 6 is highly speculative. For instance, they have only 3 strains from which to base their fitness idea in the first place - it could be that other MDR strains do not displace commensal E. coli!

- It would likely be straightforward to make a transposon library in this strain, which could then be screened for growth fitness, given the hypothesis of metabolism. This would provide a mechanistic test of their idea.

-

Other comments:

- The whole paragraph in the introduction ending on line 100 about recent studies of E. coli colonization seems like a series of anecdotes that could just be summarized in a single sentence, rather than going through all of the details.

- Line 243: it would be interesting to provide some estimates of the fitness advantage of the ExPEC strains.

- Throughout the manuscript in many places, the authors are not careful about verb tense. Many times things should be in past tense rather than the present that is in the manuscript - e.g. line 263.

- Line 333: why "incredibly"?

Decision Letter 2

Paula Jauregui, PhD

24 Aug 2023

Dear Dr. McNally,

Thank you for your patience while we considered your revised manuscript "Multi-drug resistant E. coli displace commensal E. coli from the intestinal tract, a trait associated with elevated levels of genetic diversity in carbohydrate metabolism genes." for publication as a Discovery Report at PLOS Biology. This revised version of your manuscript has been evaluated by the PLOS Biology editors, the Academic Editor, and the original reviewers.

Based on the reviews and on our Academic Editor's assessment of your revision, we are likely to accept this manuscript for publication as a Discovery Report, provided you satisfactorily address the following data and other policy-related requests.

Please note that the reviewers are not completely satisfied with the revision as the new data added still does not establish cause-and-effect in a more relevant model. Therefore, we will consider this manuscript only as a Discovery Report. For that, you need to reduce the number of main figures to a maximum of 4.

Discovery Reports describe novel and intriguing initial findings with the potential to lead to a significant new result for the field. Discovery Reports are short articles, typically with 2-4 main figures. While the research may be preliminary, studies should be advanced to the stage where observations or findings have been confirmed by independent methods or experimental approaches and obvious alternative interpretations have been ruled out. Discovery Reports are designed to work together with Update Articles to empower researchers to evaluate and share work in a way that more closely mirrors the real-world research process and create a comprehensive research story.

1. ETHICS STATEMENT:

-- Please include the full name of the IACUC/ethics committee that reviewed and approved the animal care and use protocol/permit/project license. Please also include an approval number.

-- Please include the specific national or international regulations/guidelines to which your animal care and use protocol adhered. Please note that institutional or accreditation organization guidelines (such as AAALAC) do not meet this requirement.

2. DATA POLICY:

You may be aware of the PLOS Data Policy, which requires that all data be made available without restriction: http://journals.plos.org/plosbiology/s/data-availability. For more information, please also see this editorial: http://dx.doi.org/10.1371/journal.pbio.1001797

Note that we do not require all raw data. Rather, we ask that all individual quantitative observations that underlie the data summarized in the figures and results of your paper be made available in one of the following forms:

A) Supplementary files (e.g., excel). Please ensure that all data files are uploaded as 'Supporting Information' and are invariably referred to (in the manuscript, figure legends, and the Description field when uploading your files) using the following format verbatim: S1 Data, S2 Data, etc. Multiple panels of a single or even several figures can be included as multiple sheets in one excel file that is saved using exactly the following convention: S1_Data.xlsx (using an underscore).

B) Deposition in a publicly available repository. Please also provide the accession code or a reviewer link so that we may view your data before publication.

Regardless of the method selected, please ensure that you provide the individual numerical values that underlie the summary data displayed in the following figure panels as they are essential for readers to assess your analysis and to reproduce it: Figures 1BCDEFGH, 2BCDEF, 3BCD, 4ABCDEFGH, 5ABCD, 6ABC, and Supplementary Figures S3, S4ABCDEF, S6ABC, S7ABC, S8ABC, S9, S10, S11AB.

NOTE: the numerical data provided should include all replicates AND the way in which the plotted mean and errors were derived (it should not present only the mean/average values).

Please also ensure that figure legends in your manuscript include information on where the underlying data can be found, and ensure your supplemental data file/s has a legend.

Please ensure that your Data Statement in the submission system accurately describes where your data can be found.

3. Please add size bars to microscopy pictures in Figure S5.

4. Please move the Materials and Methods to the end of the manuscript, after the discussion.

5. We suggest a change in the title: " Multi-drug resistant E. coli encoding high genetic diversity in carbohydrate metabolism genes displace commensal E. coli from the intestinal tract."

As you address these items, please take this last chance to review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the cover letter that accompanies your revised manuscript.

We expect to receive your revised manuscript within two weeks.

To submit your revision, please go to https://www.editorialmanager.com/pbiology/ and log in as an Author. Click the link labelled 'Submissions Needing Revision' to find your submission record. Your revised submission must include the following:

- a cover letter that should detail your responses to any editorial requests, if applicable, and whether changes have been made to the reference list

- a Response to Reviewers file that provides a detailed response to the reviewers' comments (if applicable)

- a track-changes file indicating any changes that you have made to the manuscript.

NOTE: If Supporting Information files are included with your article, note that these are not copyedited and will be published as they are submitted. Please ensure that these files are legible and of high quality (at least 300 dpi) in an easily accessible file format. For this reason, please be aware that any references listed in an SI file will not be indexed. For more information, see our Supporting Information guidelines:

https://journals.plos.org/plosbiology/s/supporting-information

*Published Peer Review History*

Please note that you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details:

https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/

*Press*

Should you, your institution's press office or the journal office choose to press release your paper, please ensure you have opted out of Early Article Posting on the submission form. We ask that you notify us as soon as possible if you or your institution is planning to press release the article.

*Protocols deposition*

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please do not hesitate to contact me should you have any questions.

Sincerely,

Paula

---

Paula Jauregui, PhD,

Senior Editor,

pjaureguionieva@plos.org,

PLOS Biology

------------------------------------------------------------------------

Reviewer remarks:

Reviewer #1: The authors have addressed our questions and comments reasonably and we congratulate them to this study.

Reviewer #2: The authors have not adequately responded to all the reviewer's comments, with most of the responses "extending beyond the current study".

The authors present in vitro Biolog data for 3 strains but do not expand their in vivo work to more than one MDR strain. In the very least, they should perform an experiment to see if they challenge F06 with another MDR strain do they both colonize?

How about if they challenge with another B2 UPEC that is non-MDR? Studies have shown that UPEC stays in the gut displacing commensals over long periods of time in humans (See Forde et al, from Mulvey and Schembri's groups). It would be most beneficial if the authors actually performed this key experiment.

Reviewer #3: The authors have done some work to address the reviewer feedback including Biology measurements and a comparative genomics analysis. I was disappointed not to see more of an effort to address the more preliminary aspects of the article, in particular efforts to construct a transposon library, which is effective in many E. coli strains (or at least a report of low transformation efficiency of their strains). The new additions have added impact to the paper.

I leave it to the editor as to the decision of the general interest in this topic.

Decision Letter 3

Paula Jauregui, PhD

11 Sep 2023

Dear Dr. McNally,

Thank you for the submission of your revised Discovery Report "Multi-drug resistant E. coli encoding high genetic diversity in carbohydrate metabolism genes displace commensal E. coli from the intestinal tract." for publication in PLOS Biology. On behalf of my colleagues and the Academic Editor, Sebastian Winter, I am pleased to say that we can in principle accept your manuscript for publication, provided you address any remaining formatting and reporting issues. These will be detailed in an email you should receive within 2-3 business days from our colleagues in the journal operations team; no action is required from you until then. Please note that we will not be able to formally accept your manuscript and schedule it for publication until you have completed any requested changes.

Please take a minute to log into Editorial Manager at http://www.editorialmanager.com/pbiology/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process.

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with biologypress@plos.org. If you have previously opted in to the early version process, we ask that you notify us immediately of any press plans so that we may opt out on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/.

Thank you again for choosing PLOS Biology for publication and supporting Open Access publishing. We look forward to publishing your study. 

Sincerely, 

Paula

---

Paula Jauregui, PhD,

Senior Editor

PLOS Biology

pjaureguionieva@plos.org

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Method. Supplementary methodology for histological and cytokine analysis of mouse tissues.

    (DOCX)

    S1 Table. Details of E. coli strains used for mouse colonisation and Biolog experiments.

    (XLSX)

    S2 Table. Primers and probes used for CFU quantification qPCR and cytokine qPCR.

    (XLSX)

    S3 Table. Numbers of E. coli genomes from Enterobase analysed.

    (XLSX)

    S4 Table. Pangenome size of each E. coli lineage analysed.

    (XLSX)

    S1 Fig. Heatmap of virulence factors identified in mouse colonising strains.

    (EPS)

    S2 Fig. Heatmap of AMR genes identified in mouse colonising strains.

    (EPS)

    S3 Fig. CFU of colonising bacteria in monocolonised mice measured by enumeration from UTI Chromogenic agar plates.

    CFU counts were adjusted to faecal pellet weight. Geometric average CFU of 822-E8 (black line), F084 (blue line), and F016 (orange line) is shown with geometric standard deviation, 3 replicates for each condition. Raw data used to produce figure available in S6 Data.

    (EPS)

    S4 Fig. Inflammatory histology score for sections of small intestine and colon from colonised mice and germ-free control mice.

    Small intestine histology scores for monocolonised mice (A), co-incolucated/competitive colonisation mice (B), and monocolonised mice challenged with a second strain after 1 week (C). Colon section histology scores for monocolonised mice (D), co-incolucated/competitive colonisation mice (E), and monocolonised mice challenged with a second strain after 1 week (F). Scores were assigned to inflammatory cell infiltrate (black circles), changes to epithelium (green squares) and overall mucosal architecture (blue triangles). Score of 1 indicates homeostatic mucosa while a score of 5 indicates severe inflammatory disruption. Points represent scores for individual fields of view (FoV) taken from multiple tissue sections. Raw data used to produce figure available in S7 Data.

    (EPS)

    S5 Fig. Representative histological sections of colonised mouse small intestine and colon stained with HE, 100 μm scale bar.

    Germ-free control mice are included.

    (EPS)

    S6 Fig

    Cytokine expression in the small intestine (A), caecum (B), and colon (C) of monocolonised mice 3 weeks after colonisation. Mice were colonised with a 822-E8 (black), F084 (blue), or F016 (orange). Germ-free mice were also assayed (open circles). Expression of cytokines is displayed as the delta Ct between cytokine and housekeeping gene Pol2ra, negative values indicate lower expression than housekeeping gene. Statistical significance determined with 2-way ANOVA with Tukey’s multiple comparisons, n = 3 for all conditions. Raw data used to produce figure available in S8 Data.

    (EPS)

    S7 Fig

    Cytokine expression in the small intestine (A), caecum (B), and colon (C) of co-inoculated mice 1 week after colonisation. Mice were colonised with an 822-E8 and F084 (blue, n = 5), 822-E8 and F016 (orange, n = 4), or F084 and F016 (purple, n = 5). Germ-free mice were also assayed (open circles, n = 3). Expression of cytokines is displayed as the delta Ct between cytokine and housekeeping gene Pol2ra, negative values indicate lower expression than housekeeping gene. Statistical significance determined with 2-way ANOVA with Tukey’s multiple comparisons. Raw data used to produce figure available in S9 Data.

    (EPS)

    S8 Fig

    Cytokine expression in the small intestine (A), caecum (B), and colon (C) of monocolonised mice which were challenged with a second strain 7 days after initial colonisation. Mice were colonised with 822-E8 and challenged with PBS (pink, n = 5), 822-E8 challenged with F084 (blue, n = 5), 822-E8 challenged with F016 (orange, n = 4), or F016 challenged with 822-E8 (black, n = 4). Germ-free mice were also assayed (open circles, n = 3). Expression of cytokines is displayed as the delta Ct between cytokine and housekeeping gene Pol2ra, negative values indicate lower expression than housekeeping gene. Statistical significance determined with 2-way ANOVA with Tukey’s multiple comparisons. Raw data used to produce figure available in S10 Data.

    (EPS)

    S9 Fig. Cycle threshold values for strain-specific probes assayed using DNA extracted from faecal pellets from monocolonised mice; 822-E8 specific probe (clpP) in blue, F084 specific probe (lon) in green, and F016 specific probe (prtR) in orange.

    Raw data used to produce figure available in S11 Data.

    (EPS)

    S10 Fig. Standard curves for CFU determination.

    DNA isolates from broth culture of known CFU serially 10-fold diluted and plotted against Ct for that dilution. Colour lines indicate standard curve from stock dilutions, while black lines indicate standard curves from every assay plate used for CFU quantitation. Standard curves for 822-E8 specific probe clpP (A), F084 probe lon (B), and F016 probe prtR (C). Raw data used to produce figure available in S12 Data.

    (EPS)

    S11 Fig

    Source niche for genome in dataset (A) and cumulative time of collection (B). Metadata used to produce figure available at 10.6084/m9.figshare.c.6147189.

    (EPS)

    S12 Fig. Geographic distribution of genomes in dataset, colour scale is logarithmic.

    Figure was produced in R using ggplot2 (https://ggplot2.tidyverse.org) with a map layer from Natural Earth (https://www.naturalearthdata.com/). Metadata used to produce figure available at 10.6084/m9.figshare.c.6147189.

    (EPS)

    S13 Fig

    Correlation between pangenome size and average number of resistance genes (A). Correlation between pangenome size and proportion of the lineage with 2 or more resistance genes (B).

    (EPS)

    S14 Fig. Pangenome rarefaction curves for the accessory compartment of each ST pangenome.

    (EPS)

    S15 Fig. Core genome rarefaction curves for each ST.

    (EPS)

    S16 Fig

    Pangenome total size against the proportion of genes annotated as hypothetical proteins for each ST (A). Pangenome total size against the proportion of the pangenome assigned a COG category for each ST (B).

    (EPS)

    S17 Fig. Phylogenetic tree of selected lineages of E. coli, incidence of AMR genes within the dataset and correlations between HGT and AMR gene content.

    (A) Phylogenetic tree of dataset produced from Mash distances, tip branches are coloured by ST and phylogroups are outlined. (B) The proportion of the lineage with 2 or more resistance genes of any class against the proportion of the lineage with 1 or more beta-lactamase gene. (C) Proportion of the pangenome that is associated with phage elements against the proportion of the lineage that has 2 or more resistance genes of any class. (D) Proportion of the genome predicted to be within a recombination block against the proportion of the lineage that has 2 or more resistance genes of any class. Red lines indicate linear regressions (B: R2 0.954, P-value 1.61 × 10−13 C: R2 0.369, P-value 0.0045, D: R2 0.138, P-value 0.117).

    (EPS)

    S18 Fig

    Recombination regions predicted by Gubbins in ST73 (A) and ST131 (B) lineages. Red blocks indicate putative regions of recombination. Yellow and orange track bar indicate position in reference genome. Select regions are annotated.

    (PDF)

    S1 Data. Colony forming units from co-inoculated mice as measured by ST-specific qPCR.

    Data used to produce Fig 1B–1E.

    (XLSX)

    S2 Data. Growth curves of strains used to colonise mouse in culture supernatant from competing strains.

    Data used to produce Fig 1F–1H.

    (XLSX)

    S3 Data. Colony forming units from colonised mice with subsequent challenge as measured by ST-specific qPCR.

    Data used to produce Fig 2B–2F.

    (XLSX)

    S4 Data. Colony forming units from co-housed mice with as measured by ST-specific qPCR.

    Data used to produce Fig 3B–3D.

    (XLSX)

    S5 Data. Biolog phenotypic microarray data for plate PM1.

    Data used to produce Fig 4A.

    (XLSX)

    S6 Data. Colony forming units from mice colonised by a single strain measured by plating.

    Data used to produce S3 Fig.

    (XLSX)

    S7 Data. Inflammatory scoring for histological sections of mouse small intestine and colon.

    Data used to produce S4 Fig.

    (XLSX)

    S8 Data. Expression of a panel of cytokines in the small intestine, caecum, or colon of mice colonised by a single strains, measured by qPCR.

    Data used to produce S6 Fig.

    (XLSX)

    S9 Data. Expression of a panel of cytokines in the small intestine, caecum, or colon of mice co-inoculated with 2 strains, measured by qPCR.

    Data used to produce S7 Fig.

    (XLSX)

    S10 Data. Expression of a panel of cytokines in the small intestine, caecum, or colon of mice pre-colonised with subsequent challenge, measured by qPCR.

    Data used to produce S8 Fig.

    (XLSX)

    S11 Data. Cross reactivity of ST-specific probes.

    Data used to produce S9 Fig.

    (XLSX)

    S12 Data. Standard curves for ST-specific probes used to quantify CFU.

    Data used to produce S10 Fig.

    (XLSX)

    Attachment

    Submitted filename: Response to reviewers.docx

    Attachment

    Submitted filename: final_response.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files. All genomic data used in this study can be found in a dedicated figshare repository 10.6084/m9.figshare.c.6147189.


    Articles from PLOS Biology are provided here courtesy of PLOS

    RESOURCES